`
`————————————————
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`————————————————
`
`MYLAN PHARMACEUTICALS INC.,
`MSN LABORATORIES PRIVATE LTD.,
`and MSN PHARMACEUTICALS INC.,
`Petitioners,
`
`v.
`
`BAUSCH HEALTH IRELAND LIMITED,
`Patent Owner.
`
`————————————————
`Case IPR2022-007221
`Patent 7,041,786
`————————————————
`
`PETITIONERS’ REQUEST FOR ORAL ARGUMENT
`37 C.F.R. §42.70(a)
`
`1 IPR2023-00016 has been joined with this proceeding.
`
`
`
`Petitioner Mylan Pharmaceuticals Inc. requests oral argument on the
`
`unpatentability of claims 1-6 of U.S. Patent No. 7,041,786 as instituted and
`
`briefed, as well as on any pending motions.
`
`Petitioner requests 45 minutes per side of oral argument. The oral argument
`
`is scheduled to be held June 14, 2023, pursuant to the September 14, 2022,
`
`scheduling order (Paper No. 17). Because the order advised that at least two
`
`judges will appear remotely by video, Petitioner Mylan believes oral argument
`
`may be most efficiently held virtually by videoconference. However, Petitioner
`
`Mylan is ready and willing to appear in person at the USPTO Regional Office in
`
`San Jose if this would be helpful to the Board.
`
`Date: May 3, 2023
`
`Respectfully submitted,
`
`/Jad A. Mills/
`Jad A. Mills, Reg. No. 63,344
`Counsel for Mylan Pharmaceuticals Inc.
`
`2
`
`
`
`CERTIFICATE OF SERVICE
`
`I certify a true and correct copy of this paper was served today to the email
`
`correspondence addresses of the patent owner and the joinder petitioners as follows:
`
`Justin J. Hasford
`
`justin.hasford@finnegan.com
`
`Bryan C. Diner
`
`bryan.diner@finnegan.com
`
`Joshua Goldberg
`
`joshua.goldberg@finnegan.com
`
`Caitlin O’Connell
`
`caitlin.o’connell@finnegan.com
`
`Kyu Yun Kim
`
`kyuyun.kim@finnegan.com
`
`Kassandra Officer
`
`kassandra.officer@finnegan.com
`
`and on MSN’s counsel at:
`
`Andrew Larsen
`
`alarsen@merchantgould.com
`
`Melissa Hayworth
`
`mhayworth@merchantgould.com
`
`Date: May 3, 2023
`
`Respectfully submitted,
`
`/Robyn Moriarty/
`Robyn Moriarty
`
`3
`
`